Antituberculosis drug-induced hepatotoxicity in Iranian tuberculosis patients: Role of isoniazid metabolic Polymorphism

Iranian Journal of Pharmaceutical Research

Volumn 10, Issue 3, 2011, Pages 633-639

  Sistanizad, Mohammad ^a,b   Azizi, Ebrahim ^b   Khalili, Hosein ^b   Hajiabdolbaghi, Mahboobeh ^c   Gholami, Kheirollah ^b   Mahjub, Reza ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antituberculosis; Hepatotoxicity; Isoniazid; Polymorphism; Tuberculosis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IRAN; LIVER TOXICITY; LUNG TUBERCULOSIS; MALE; PHENOTYPE; PROSPECTIVE STUDY;

EID: 84856957843     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R and Sterling TR. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care. Med. (2006) 174: 935-52.
2. Kobarfard F, Velayati A, Mosaddegh A, Massjedi MR and Farnia P. Tuberculosis and traditional medicine: fighting the oldest infectious disease, using the oldest source of medicine. Iranian J. Pharm. Res. (2004) 3: 13-13.
3. Kobarfard F. Tuberculosis and traditional medicine: fighting the oldest infectious disease using the oldest source of medicines. Iranian J. Pharm. Res. (2004) 2: 71-72.
4. rd ed. Geneva, WHO (2003).
5. Abbasi Nazari A, Kobarfard F, Tabarsie P, Azimi M and Salamzadeh J. Effect of antituberculosis regimen containing ethambutol on serum magnesium level in pulmonary tuberculosis patients. Iranian J. Pharm. Res. (2009) 8: 33-36.
6. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY and Lee SD. Polymorphism of the n-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology (2002) 35: 883-9.
7. Swasey LK. Hepatotoxicity to isoniazid. A case report. Ariz. Med. (1974) 31: 17-9.
8. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ and Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. (2008) 23: 192-202.
9. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, Nicod L, Desmeules J and Hochstrasser D. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. (2006) 62: 423-9.
10. Seifart HI, Parkin DP, Botha FJ, Donald PR and Van Der Walt BJ. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol. Drug Saf. (2001) 10: 127-34.
11. Sim E, Lack N, Wang CJ, Long H, Westwood I, Fullam E and Kawamura A. Arylamine n-acetyltransferases: structural and functional implications of polymorphisms. Toxicology (2008) 254: 170-83.
12. Evans DA, Manley KA and McKusick KV. Genetic control of isoniazid metabolism in man. Br. Med. J. (1960) 2: 485-91.
13. Kilbane AJ, Silbart LK, Manis M, Beitins IZ and Weber WW. Human n-acetylation genotype determination with urinary caffeine metabolites. Clin. Pharmacol. Ther. (1990) 47: 470-7.
14. Evans DA. Ethnic differences in reactions to drugs and xenobiotics. Acetylation. Prog. Clin. Biol. Res. (1986) 214: 209-42.
15. Lin HJ, Han CY, Lin BK and Hardy S. Slow acetylator mutations in the human polymorphic n-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am. J. Hum. Genet. (1993) 52: 827-34.
16. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol. Ther. (1976) 19: 610-25.
17. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR and Corcoran GB. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science (1976) 193: 901-3.
18. Gent WL, Seifart HI, Parkin DP, Donald PR and Lamprecht JH. Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients. Eur. J. Clin. Pharmacol. (1992) 43: 131-6.
19. Sarich TC, Youssefi M, Zhou T, Adams SP, Wall RA and Wright JM. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch. Toxicol. (1996) 70: 835-40.
20. Noda A, Hsu KY, Noda H, Yamamoto Y and Kurozumi T. Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine? J. UOEH. (1983) 5: 183-90.
21. Danan G and Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. (1993) 46: 1323-30.
22. Hutchings A, Monie RD, Spragg B and Routledge PA. High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids. J. Chromatogr. (1983) 277: 385-90.
23. Pariente-Khayat A, Rey E, Gendrel D, Vauzelle-Kervroedan F, Cremier O, dAthis P, Badoual J, Olive G and Pons G. Isoniazid acetylation metabolic ratio during maturation in children. Clin. Pharmacol. Ther. (1997) 62: 377-83.
24. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M and Vaziri S. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment. Pharmacol. Res. (2005) 51: 353-8.
25. Aziz H, Shubair M, Debari VA, Ismail M and Khan MA. Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection. Curr. Med. Res. Opin. (2006) 22: 217-21.
26. Evans DA. n-Acetyltransferase. Pharmacol. Ther. (1989) 42: 157-234.
27. Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, Miyazaki Y, Kobayashi T, Yoshiura K, Niikawa N, Wen CY, Isomoto H, Shikuwa S, Omagari K, Mizuta Y, Kohno S and Tsukamoto K. NAT2 6A, a haplotype of the n-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol. (2007) 13: 6003-8.
28. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow HR and Keiser HR. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin. Pharmacol. Ther. (1975) 18: 70-9.
29. Singh J, Arora A, Garg PK, Thakur VS, Pande JN and Tandon RK. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad. Med. J. (1995) 71: 359-62.
30. Kopanoff DE, Snider DE Jr. and Caras GJ. Isoniazid-related hepatitis: a U.S. public health service cooperative surveillance study. Am. Rev. Respir. Dis. (1978) 117: 991-1001.
31. LoBue PA and Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am. J. Respir. Crit. Care. Med. (2003) 168: 443-7.
32. Marzuki OA, Fauzi AR, Ayoub S and Kamarul Imran M. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med. J. (2008) 49: 688-93.
33. Bakayev VV, Mohammadi F, Bahadori M, Sheikholslami M, Javeri A, Masjedi MR and Velayati AA. Arylamine n-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur. J. Clin. Pharmacol. (2004) 60: 467-71.
34. Torkaman-Boutorabi A, Hoormand M, Naghdi N, Bakhshayesh M and Milanian I. Genotype and allele frequencies of n-acetyltransferase 2 and glutathione S-transferase in the Iranian population. Clin. Exp. Pharmacol. Physiol. (2007) 34: 1207-11.
35. Sardas S, Lahijany B, Cok I and Karakaya AE. n-Acetylation phenotyping with sulfamethazine in an Iranian population. Pharmacogenetics (1993) 3: 131-4.
36. ONeil WM, Drobitch RK, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR and Svensson CK. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics (2000) 10: 171-82.
37. Notarianni LJ, Dobrocky P, Godlewski G, Jones RW and Bennett PN. Caffeine as a metabolic probe: NAT2 phenotyping. Br. J. Clin. Pharmacol. (1996) 41: 169-73.
38. Setiabudy R, Kusaka M, Chiba K, Darmansjah I and Ishizaki T. Dapsone n-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial. Clin. Pharmacol. Ther. (1994) 56: 142-53.
39. Schaberg T, Rebhan K and Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J. (1996) 9: 2026-30.
40. Shakya R, Rao BS and Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann. Pharmacother. (2004) 38: 1074-9.